Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

Summary

The 1-year graft-free survival rate at 12 months post transplant was 90%, which is clinically significant Graft and patient survival were 92% and 98%, respectively Idefirix was generally well tolerated with a safety...